No Data
Hongbo Pharmaceuticals (301230.SZ) shareholder Zhongfu Jishi completed a 1% shareholding reduction.
Hengbo Pharmaceuticals (301230.SZ) announced that the company's shareholder, Peking Zhongfu Jishi Investment Center (Limited Partnership) (referred to as...
Hongbo Pharmaceuticals (301230.SZ) plans to grant 1.23 million restricted stocks at a grant price of 12.35 yuan per share.
Hongbo Pharmaceuticals (301230.SZ) disclosed the 2024 Restricted Stock Incentive Plan (draft), with the company planning to grant stocks to incentivize...
Hongbo Pharmaceutical (301230) company information update report: steady revenue growth in the first three quarters, profit under temporary pressure.
Steady revenue growth in the first three quarters, with significant fluctuations in profit due to the decline in gross margin of sub-sectors. In 2024Q1-3, the company achieved revenue of 0.391 billion yuan, a year-on-year increase of 6.59%; net income attributable to equity holders was 15.24 million yuan, a year-on-year decrease.
Hongbo Pharmaceutical: Report for the third quarter of 2024
Hongbo Pharma (301230.SZ) released its performance for the first three quarters, with a net income of 15.2436 million yuan, a 66.81% year-on-year decrease.
Hongbo Medicine (301230.SZ) released the third quarter report for the first three quarters of 2024, during the reporting period the company achieved revenue...
Hongan Pharmaceutical (301230.SZ): The equity distribution for the first half of 2024 is 1 yuan per share. The ex-dividend date is October 24th.
Golden 汇October 17th丨Hongbo Pharmaceutical (301230.SZ) announced that the company's interim equity distribution plan for the first half of 2024 is as follows: based on the total share capital of the company, excluding the repurchased 2,046,200 shares, the remaining 137,540,405 shares will be distributed to all shareholders at a rate of 1.0 RMB cash per 10 shares. The equity registration date is October 23, 2024, and the ex-rights and ex-dividend date is October 24, 2024.
No Data
No Data